Delivery Order SPE2DB24D1205-SPE2DB25FCZKF
- Not listed
- The Defense Logistics Agency awarded a $10,662.57 firm fixed price delivery order to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count packages) on August 11, 2025, with an ultimate completion date of September 2, 2025. This non-set-aside contract represents a competitive award for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for the Defense Logistics Agency's Medical...
- The Defense Logistics Agency awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of TAGRISSO 40 mg tablets (30-count packages). This firm fixed price contract, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a direct fulfillment of pharmaceutical needs within the federal medical supply chain. The award was competitively procured with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count supply) valued at approximately $53.3K. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 14, 2025, awarded on July 24, 2025. The pharmaceutical product will be supplied to the federal government through AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for TAGRISSO 40 mg tablets (30-count packages). The contract, valued at $10,641.07, is scheduled for completion by August 13, 2025, and represents a non-competitive set-aside delivery order placed against the company's existing Indefinite Delivery Contract with DLA. This award falls under...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for Tagrisso 80 mg tablets (30-count packages). This contract utilizes firm fixed pricing with an ultimate completion date of August 11, 2025. The award was competitively awarded with no set-aside designation, and performance will be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents a child contract under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $21,325.14 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). The contract is firm fixed price with no set-aside designation, reflecting a competitive award. Performance will be completed by August 20, 2025, with the contract awarded on July 30, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $21,325.14 for TAGRISSO 80 mg tablets (30-count units) on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price, competitively awarded delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TAGRISSO is a prescription oncology medication used primarily in the treatment of...
- The Defense Logistics Agency awarded a delivery order valued at approximately $32,000 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of August 15, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in...
- The Defense Logistics Agency awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of TAGRISSO 40 mg tablets (30-count units) under a firm fixed price contract. This delivery order, issued on July 30, 2025, with an ultimate completion date of August 20, 2025, represents a non-set-aside, competitively awarded procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TAGRISSO is a prescription...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZKFDelivery Order
The Defense Logistics Agency awarded a $10,662.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count) on August 11, 2025, with completion scheduled for September 2, 2025. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999 ceiling value through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. The company's capacity to fulfill this requirement reflects its competitive standing within the DLA's pharmaceutical procurement portfolio and its established role in supporting Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 8/11/25 |